| Generic name | Vincristine sulfate liposome injection |
| Pronunciation | vin-KRIS-teen SUHL-feyt |
| Brand name(s), other common name(s) | Marqibo® |
| Drug type | Antimitotic |
| How the drug is given | Intravenously (IV) (fatal if given by other routes) |
Indications and Usage
Vincristine sulfate liposome injection is FDA approved for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
Side effects needing medical attention
Constipation; bowel obstruction; nausea; fever; fatigue; diarrhea; decreased appetite; insomnia; low blood cell counts; pneumonia; life-threatening low blood pressure; infection; peripheral sensory and motor neuropathy; lack of strength; muscular weakness; respiratory distress; respiratory failure; pain; abdominal pain; hypotension; mental status changes; cardiac arrest.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.